Medication info

Olmesartan Medoxomil and Amlodipine Tablets 5/40 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
You & Life Science Co., Ltd.
Appearance
Pale yellow round film-coated tablets
Packaging
30 tablets/PTP[((10 tablets/PTP) X3)]
Approval status
Expired

MFDS item code 202000604 · Approved 2020.02.04

This product's status changed to Expired on 2025.02.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 milligrams once daily. This drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: For patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment (see Precautions for Use 2. Contraindications). ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
Pediatric patients under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
You & Life Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or olmesartan medoxomil. This medicine effectively lowers blood pressure and helps reduce the risk of cardiovascular disease. When patients have difficulty controlling their blood pressure, taking this medication will contribute to improving their condition. It aids in maintaining a healthy lifestyle through stable blood pressure management. This medication is used in the treatment of essential hypertension.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 milligrams once daily. This drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: For patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment (see Precautions for Use 2. Contraindications). ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

Pediatric patients under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm or even death to the fetus and newborn when taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to certain patients, such as those with allergies to the active ingredients or similar substances, pregnant or breastfeeding women, patients with severe liver or heart problems, and patients undergoing kidney dialysis, as it may pose risks. Patients with a deficiency of fluids or salts may develop low blood pressure, and their condition must be carefully monitored during the initial administration; patients with acute hypotension due to vascular dilation or those with heart diseases also require caution. This medication may cause various adverse reactions, including dizziness, headache, hypotension, gastrointestinal issues, skin rashes, myalgia, and other symptoms, so caution should be exercised. Particularly, patients with impaired kidney function or heart failure may experience worsening kidney function or electrolyte imbalance, necessitating regular check-ups. This medication can interact with other drugs, so if taking other medications, patients must inform their doctor or pharmacist, and it is advisable to avoid taking it with grapefruit juice. During pregnancy, the use of this medication may pose risks to the fetus; therefore, individuals planning to become pregnant or who are pregnant must consult with healthcare professionals. Breastfeeding women should consult with healthcare professionals regarding whether to continue breastfeeding or discontinue the medication, as it may pass into breast milk. This medication has not been established for safety and efficacy in children under 18 years of age and is not recommended for them. In elderly patients, decreased kidney and liver function may alter the drug's effects and side effects; therefore, caution during administration is needed, and starting with a lower dose is usually recommended. In case of overdose, symptoms such as hypotension and arrhythmia may occur; if symptoms present, medical attention should be sought immediately, and blood pressure and heart function need to be closely monitored. This medication should be stored in a tightly sealed container, protected from moisture and heat, and kept out of reach of children; it is advisable not to transfer it to another container.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, altered perception, sensory impairment, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, upper abdominal pain, rash, urticaria, muscular tension, limb pain, low back pain, frequency of urination, erectile dysfunction, peripheral edema, edema, pitting edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin and hematocrit, cholelithiasis, female breast neoplasm, exacerbation of cerebral infarction, gum bleeding, chest pain, cold, increased CRP, fever, hemoptysis, excessive sneezing, runny nose, laryngitis, arthritis, flank pain, generalized pain, hypoglycemia, weight loss, heartburn, gastroenteritis, herpes zoster, diplopia, insomnia, asthenia, angioedema, chronic malabsorption syndrome - similar intestinal disease, rhabdomyolysis, acute renal failure, hair loss, itching, autoimmune hepatitis, angioedema, rhabdomyolysis, elevated serum creatinine, hair loss, itching, urticaria, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is best kept at room temperature between 1 and 30 degrees Celsius. This storage method preserves the effectiveness of the medication safely.

Appearance and packaging

Appearance

Pale yellow round film-coated tablets

Package unit

30 tablets/PTP[((10 tablets/PTP) X3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.